PI-103 Hydrochloride
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
PI-103是PI3K / Akt和mTOR的双重抑制剂,对P110α、P110β、P110γ、P110和mTOR的IC50值分别为0.002 μM、0.003 μM、0.003 μM、0.015 μM和0.030 μM[1]。
PI3K / AKT / mTOR途径是细胞内信号传导途径,在调节细胞周期中起重要作用。PI3K / Akt / mTOR途径与细胞增殖、癌症和寿命直接相关。研究表明,在癌症中,PI3K / Akt信号传导途径的活化与不良预后密切相关,抑制该途径是一种很有希望的治疗手段[2,3]。
PI-103是PI3K / Akt和mTORC1的选择性抑制剂。在PI3K / Akt、mTORC1和ERK / MAPK信号活化的白血病细胞株(MOLM14,OCI-AML3和MV4-11)中,1 μM PI-103通过抑制PI3K / Akt和mTORC1的活性,阻断细胞增殖[4]。在HCC细胞系Huh7细胞中,PI-103单独给药或与sorafenib共同作用,以剂量依赖的方式抑制PI3K / Akt和mTORC1途径,最终抑制细胞增殖[5]。使用30 nM PI-103处理U87MG胶质母细胞瘤细胞,显著抑制PI3K / Akt和mTORC1的磷酸化[1]。在神经母细胞瘤细胞系SK-N-BE(2)和含有扩增MYCN的IMR-32中,PI-103通过抑制PI3K / Akt和mTORC1的活性,以时间和浓度依赖性的方式抑制细胞生长[3]。
在MYCN突变SK-N-BE(2)异种移植的裸鼠模型中,PI-103(10 mg/kg)腹腔给药可通过抑制PI3K / mTOR信号通路显著减少肿瘤体积指数和肿瘤重量[1]。
参考文献:?
[1].?? ?Raynaud, F.I., et al., Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther, 2009. 8(7): p. 1725-38.
[2].?? ?Hambright, H.G., et al., Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget, 2015.
[3].?? ?Segerstrom, L., et al., Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer, 2011. 129(12): p. 2958-65.
[4].?? ?Park, S., et al., PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 2008. 22(9): p. 1698-706.
[5].?? ?Gedaly, R., et al., PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res, 2010. 30(12): p. 4951-8
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 384.82 |
Cas No. | 371935-79-4 |
Formula | C19H17ClN4O3 |
Synonyms | PI 103 hydrochloride;PI103 hydrochloride |
Solubility | insoluble in H2O; insoluble in EtOH; ≥19.25 mg/mL in DMSO |
Chemical Name | 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol;hydrochloride |
SDF | Download SDF |
Canonical SMILES | C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O.Cl |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |